Skip to main content

NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.

Publication ,  Journal Article
Benson, AB; Venook, AP; Adam, M; Chang, G; Chen, Y-J; Ciombor, KK; Cohen, SA; Cooper, HS; Deming, D; Garrido-Laguna, I; Grem, JL; Haste, P ...
Published in: J Natl Compr Canc Netw
August 2024

The determination of an optimal treatment plan for an individual patient with rectal cancer is a complex process. In addition to decisions relating to the intent of rectal cancer surgery (ie, curative or palliative), consideration must also be given to the likely functional results of treatment, including the probability of maintaining or restoring normal bowel function/anal continence and preserving genitourinary functions. Particularly for patients with distal rectal cancer, finding a balance between curative-intent therapy while having minimal impact on quality of life can be challenging. Furthermore, the risk of pelvic recurrence is higher in patients with rectal cancer compared with those with colon cancer, and locally recurrent rectal cancer is associated with a poor prognosis. Careful patient selection and the use of sequenced multimodality therapy following a multidisciplinary approach is recommended. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Rectal Cancer, including the addition of endoscopic submucosal dissection as an option for early-stage rectal cancer, updates to the total neoadjuvant therapy approach based on the results of recent clinical trials, and the addition of a "watch-and-wait" nonoperative management approach for clinical complete responders to neoadjuvant therapy.

Duke Scholars

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

August 2024

Volume

22

Issue

6

Start / End Page

366 / 375

Location

United States

Related Subject Headings

  • Rectal Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Medical Oncology
  • Humans
  • Combined Modality Therapy
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y.-J., Ciombor, K. K., … Gurski, L. (2024). NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw, 22(6), 366–375. https://doi.org/10.6004/jnccn.2024.0041
Benson, Al B., Alan P. Venook, Mohamed Adam, George Chang, Yi-Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, et al. “NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.J Natl Compr Canc Netw 22, no. 6 (August 2024): 366–75. https://doi.org/10.6004/jnccn.2024.0041.
Benson AB, Venook AP, Adam M, Chang G, Chen Y-J, Ciombor KK, et al. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 Aug;22(6):366–75.
Benson, Al B., et al. “NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.J Natl Compr Canc Netw, vol. 22, no. 6, Aug. 2024, pp. 366–75. Pubmed, doi:10.6004/jnccn.2024.0041.
Benson AB, Venook AP, Adam M, Chang G, Chen Y-J, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Jones F, Gurski L. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 Aug;22(6):366–375.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

August 2024

Volume

22

Issue

6

Start / End Page

366 / 375

Location

United States

Related Subject Headings

  • Rectal Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Medical Oncology
  • Humans
  • Combined Modality Therapy
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis